Vulvar Lesion Found in 37-Year-Old Woman

For patients with HR–positive/HER2-negative breast cancer, neoadjuvant patritumab deruxtecan with or without letrozole showed antitumor activity.

Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

Six-year data from the OlympiA trial support olaparib as a standard of care in BRCA-mutated, high-risk, HER2-negative primary breast cancer.

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

For patients with hormone receptor-positive and HER2-low breast cancer, T-DXd elicited higher levels of PFS despite time to progression and disease burden.

Findings from a multi-institutional study show an increased risk of developing high-grade immune-related AEs among select older patients with early-stage breast cancer.